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Radiographic image guidance has emerged as the new paradigm for patient positioning, target
localization, and external beam alignment in radiotherapy. Although widely varied in modality and
method, all radiographic guidance techniques have one thing in common—they can give a signifi-
cant radiation dose to the patient. As with all medical uses of ionizing radiation, the general view is
that this exposure should be carefully managed. The philosophy for dose management adopted by
the diagnostic imaging community is summarized by the acronym ALARA, i.e., as low as reason-
ably achievable. But unlike the general situation with diagnostic imaging and image-guided surgery,
image-guided radiotherapy IGRT adds the imaging dose to an already high level of therapeutic
radiation. There is furthermore an interplay between increased imaging and improved therapeutic
dose conformity that suggests the possibility of optimizing rather than simply minimizing the
imaging dose. For this reason, the management of imaging dose during radiotherapy is a different
problem than its management during routine diagnostic or image-guided surgical procedures. The
imaging dose received as part of a radiotherapy treatment has long been regarded as negligible and
thus has been quantified in a fairly loose manner. On the other hand, radiation oncologists examine
the therapy dose distribution in minute detail. The introduction of more intensive imaging proce-
dures for IGRT now obligates the clinician to evaluate therapeutic and imaging doses in a more
balanced manner. This task group is charged with addressing the issue of radiation dose delivered
via image guidance techniques during radiotherapy. The group has developed this charge into three
objectives: 1 Compile an overview of image-guidance techniques and their associated radiation
dose levels, to provide the clinician using a particular set of image guidance techniques with enough
data to estimate the total diagnostic dose for a specific treatment scenario, 2 identify ways to
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4042 Murphy et al.: Imaging dose during image-guided radiotherapy 4042reduce the total imaging dose without sacrificing essential imaging information, and 3 recommend
optimization strategies to trade off imaging dose with improvements in therapeutic dose delivery.
The end goal is to enable the design of image guidance regimens that are as effective and efficient
as possible. © 2007 American Association of Physicists in Medicine. DOI: 10.1118/1.2775667TABLE OF CONTENTS
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I. INTRODUCTION
In an editorial in the British Journal of Radiology, Aird1
addresses the issue of dose delivered to the rest of the body
during external-beam radiotherapy. This concomitant
“extra-target” dose includes external linac head leakage
and scatter, internal direct and scattered therapy dose outside
the target volume, as well as nontherapeutic doses from im-
aging for planning and delivery. Total concomitant dose is
increasing steadily with the introduction of more imaging
procedures to the treatment process. However, much of this
exposure is only qualitatively monitored, and some is not
monitored at all. Aird maintains that because this cumulative
extra-target dose has a negative biological effect even within
the context of radiotherapy, it is important that the radiation
therapy community assess its cost and benefit. This task
group was formed to contribute to this process by compiling
data on concomitant imaging dose and identifying ways for it
to be reduced or optimized.
Image-guided radiotherapy IGRT makes use of many
different imaging techniques, using modalities ranging from
portal imaging to fluoroscopy to megavoltage cone-beam CT
and following regimens as simple as a single setup image or
as complex as intrafraction tumor tracking.2–5 The total im-
aging radiation dose experienced by a patient can include
multiple CT scans for planning, pretreatment fluoroscopic
studies to analyze tumor motion, and a series of interfraction
and intrafraction images for target localization. The delivery
of this dose can be spread out over several weeks during
conventional radiotherapy or confined to a short time for
hypofractionated radiotherapy and radiosurgery. Imaging
dose can be concentrated at the skin or distributed through-
out the anatomical volume of interest. Given these circum-
stances it is no longer safe to consider the dose from only
one imaging procedure at a time or to assume that the cumu-
lative imaging dose is negligible compared to the therapeutic
dose.
Data for the dose delivered by the various radiographic
imaging modalities being used during radiation therapy are
presently scattered widely through the literature, making it
4043 Murphy et al.: Imaging dose during image-guided radiotherapy 4043difficult to estimate the total dose that the patient will receive
during a particular treatment scenario. This problem is com-
pounded by the fact that equipment configurations such as
source/patient distance developed for radiotherapy guidance
often differ significantly from their diagnostic imaging coun-
terparts and by the fact that many of these imaging configu-
rations have only recently come into clinical use. Finally, the
different imaging modalities deliver very different spatial
distributions of dose resulting in significantly different physi-
ological risks. This makes it difficult to synthesize a com-
plete picture of the patient’s exposure. To manage total im-
aging dose one must first know what it is; therefore the
primary goal of this task group report is to collect into one
place enough data to allow the clinical practitioner to make
an informed estimate of the total imaging dose delivered to
the patient during the complete treatment process. Although
precise dose estimation in radiology and radiation therapy is
a complex and sometimes controversial problem we consider
that the data in this report are adequate for about a factor of
2 estimate of air kerma and effective dose. This degree of
precision should allow clinicians to make reasonably in-
formed judgments about their image-guidance procedures.
I.A. The current and emerging uses of imaging during
radiation therapy
Until the late 1990s, imaging for radiotherapy was con-
fined to the acquisition of a CT study for treatment planning,
one or two simulation images for setup, and one or two por-
tal images at the beginning of selected treatment fractions.
This practice was based on the assumption that the patient’s
anatomy exposed to the treatment beam was tolerant of
alignment errors of the order of 5–15 mm. The development
of conformal 3D therapy, intensity-modulated radiotherapy
IMRT, and frameless stereotactic radiosurgery has reduced
the alignment error tolerance to a few millimeters for targets
that move and deform during the treatment process. Image
guidance was introduced to deal with these more challenging
treatment scenarios. Image-guided radiotherapy now in-
volves multiple imaging procedures for planning, simulation,
setup, and intrafraction monitoring.
This task group is concerned with transmission-type ra-
diographic imaging using x rays. Emission-type imaging
nuclear medicine, PET, SPECT, although entering into
wider use during the planning process, involves a fundamen-
tally different type of dosimetry than transmission radiogra-
phy and hence has not been included in the scope of this
report. Nevertheless, anytime it is used, the clinician should
consider its contribution to the total dose. Ultrasound and
magnetic resonance imaging, which are also entering into
widespread use for radiotherapy, do not involve ionizing ra-
diation and thus do not fall within the scope of this report.
During the planning process, CT is almost always used to
contour the target and critical structures. CT can now be
done in either axial, spiral, or cone-beam mode. PET and
SPECT images are sometimes fused with the planning CT to
enhance specificity and sensitivity to the tumor and involved
organs.
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imaging is used to characterize the motion. Tumor motion
margins due to respiration or other influences have conven-
tionally been assessed prior to treatment via multiple CT
studies fast, slow, breathhold, etc..6 The development of
breathing-correlated CT now often referred to as 4D CT
allows one to obtain a temporal sequence of 3D image stud-
ies that chronicle the anatomy during the breathing cycle.
This technique is especially useful to accommodate and ana-
lyze breathing motion. However, a 4D CT binned into ten
breathing phases that approximately preserve 3D CT image
quality will be acquired at a total dose that is at least several
times that of a single high-quality CT and potentially as
much as the cumulative dose from ten individual CTs.
If organ motion is going to be accommodated in a plan-
ning target volume PTV margin then the CT can provide
the margin information. If the treatment plan involves active
motion management during treatment, then pretreatment
fluoroscopic studies may be required to characterize the tra-
jectory of the moving tumor. These trajectories form the ba-
sis for setting up a motion management scheme using either
breathholding, beam gating, or active target tracking.
Image-guided patient setup requires simulation images in
addition to the planning CT study. These images, which de-
fine the patient treatment position, have traditionally been
obtained via film or electronic imaging using a kV simulator
that is separate from the planning CT. Modern virtual CT
simulation allows one to calculate digitally reconstructed ra-
diographs DRRs directly from the planning CT to use as
the simulation images. This avoids the additional imaging
dose and positioning error contributed by a separate simula-
tion procedure and is therefore a positive development in the
management of concomitant dose.
Patient setup at the beginning of each fraction can now be
done either with portal imaging, diagnostic x-ray imaging, or
in-room CT both conventional and cone-beam, kilovoltage,
and megavoltage. In-room CT allows soft-tissue targets to
be precisely aligned within the coordinate frame of the beam
delivery system and can in principle provide setup images at
the start of every fraction. Cone-beam CT uses either the
therapy beam itself or a gantry-mounted kilovoltage source
and detector, thus eliminating the need for an independent
CT scanner in the treatment room. TomoTherapy7,8 provides
megavoltage fan-beam CT integrated with the treatment de-
livery system.
Intrafraction motion of the target due to either patient
movement or internal physiological functions such as breath-
ing can be monitored by dual radiographic x-ray imaging,
fluoroscopy, or portal imaging using an electronic portal im-
aging device EPID in cine mode.
Respiratory motion during treatment presents the most
difficult target alignment problem and is presently being ad-
dressed via a number of management and tracking tech-
niques see for example Bortfeld and Chen9 and the refer-
ences therein, and Keall et al.10. Many of these motion
management techniques, including beam gating and dynamic
tracking, require both pretreatment analysis of the motion
trajectories via diagnostic fluoroscopy and/or 4D CT and in-
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time, the most precise and at the same time the most dose
intensive real-time monitoring is done via dual orthogonal
fluoroscopes that continually image the treatment site
throughout the fraction.11 Therefore real-time management
of respiratory motion potentially involves the most radio-
graphic exposure of all image-guided radiotherapy proce-
dures.
The insertion of both brachytherapy seeds and HDR
sources is done under fluoroscopic and/or CT guidance. This
has much in common with fluoroscopy used during surgical
procedures, and the cumulative diagnostic dose can be con-
siderable.
I.B. The need for imaging dose management
Exposure to ionizing radiation presents two potential
health hazards—the risk of deterministic injury such as skin
burns and cataracts and the probabilistic stochastic risk of
inducing cancer or genetic defects. The danger of determin-
istic injury from prolonged fluoroscopy12 has been graphi-
cally demonstrated by several instances of severe burns fol-
lowing poorly monitored image-guided surgical
interventions.13 Stochastic risk enters more broadly as a re-
sult of concomitant dose from both the therapy beam and
from the imaging procedures. Concern over concomitant
dose from the therapy beam itself has been broadened to
include not only LINAC leakage but also secondary radia-
tion including neutrons generated from the larger number
of monitor units MUs that are characteristic of IMRT.14–16
Even though radiation therapy patients are already being
exposed to very high and localized doses of radiation, the
additional radiation from imaging has an associated risk and
should be kept low.16 Dose minimization, however, must be
within a context of relative cost versus benefit that will vary
from patient to patient. A 20 year old being treated via
image-guided radiosurgery for an arterio-venous malforma-
tion assumes a stochastic risk from imaging radiation that is
fundamentally different from a 70 year old being treated via
image-guided IMRT for prostate cancer. Children are ten
times more radiation sensitive than adults, and girls are more
sensitive than boys.17,18 Therefore imaging dose should be
managed on a case-by-case basis.
Concerns over the risk associated with concomitant expo-
sure during radiotherapy already account for the limits on
leakage and background from the primary therapy beam:
“The absorbed dose rate due to leakage radiation excluding
neutrons at any point outside the maximum sized useful
beam at the normal treatment distance shall not exceed 0.2%
of the absorbed dose rate on the central axis at the treatment
distance.”19 For a 60 Gy treatment delivered over 30 frac-
tions there will be less than 120 mGy of megavoltage radia-
tion leakage. A conventional portal film requires
50–100 mGy of megavoltage dose, while an EPID can re-
quire 10–50 mGy per image. If daily AP and lateral EPID
portal images are acquired for setup over 30 fractions,20,21
the total concomitant dose can be significantly more than the
limit for background dose from the beam and can increase
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gressive schedule of portal imaging may not be common, it
illustrates the imaging dose budget that must be considered
when high targeting precision is required. Similarly, one CT
study 30–50 mGy per fraction to assist daily setup would
deliver a total of 500–1500 mGy of diagnostic-energy radia-
tion to the patient. Although the energy and field of exposure
differ for beam leakage, portal imaging, and CT, making di-
rect comparison problematic, the imaging doses are clearly
not negligible. The health and safety considerations that un-
derlie the limit on therapy beam background dose should
therefore be considered as relevant for imaging exposures as
well.
It is especially important for practitioners of IGRT to rec-
ognize that most of the imaging techniques they employ will
deliver a qualitatively different kind of radiation distribution
than the therapy beam itself. In particular, planar kilovoltage
imaging presents the possibility of deterministic skin injury
because the maximum dose is at the skin’s surface. Therefore
entrance skin dose is one standard measure of diagnostic
imaging dose. One should also be aware that both the direct
and scattered treatment beam adds skin dose, thus pushing
the total skin dose closer to the levels associated with deter-
ministic injury.
Other users of interventional radiographic imaging, e.g.,
image-guided surgery and intraoperative fluoroscopy, are be-
coming increasingly aware of the cumulative dose the patient
receives during the procedure and are exploring ways to re-
duce the radiation dose without giving up valuable imaging
information.22
I.C. Dose management
It is not within the charge of this task group to recom-
mend total allowable imaging doses, as this requires radio-
logical analysis that is beyond the expertise of the group.
What this report provides is dose information and guidelines
to manage the dose in the spirit of the ALARA convention.23
We identify three steps in the dose management process:
1 Assessment, 2 reduction, and 3 optimization. Assess-
ment consists of estimating the total imaging dose that the
patient will receive during a given IGRT treatment regimen.
The primary purpose of this task group report is to provide
the necessary data to make this assessment, quantified in
units that allow approximate intercomparison and summing
among modalities. Reduction consists of refining the imag-
ing regimen or technique to eliminate a dose that does not
contribute to the information needed to plan, set up, or moni-
tor the patient. Diagnostic imaging technologies adapted for
IGRT can deliver an unnecessary dose that is either outside
the useful field of view FOV or beyond the minimum sam-
pling frequency needed to document patterns of target mo-
tion. For example, if a patient is undergoing respiratory-
gated treatment during which the target position is monitored
fluoroscopically, the temporal motion of the target can be
adequately observed at a sampling rate considerably less
than the fluoroscopic standard of 30 frames per second. Fi-
nally, the imaging regimen can be optimized by recognizing
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is reduced, but at the expense of more diagnostic dose else-
where. At some point, a cost/benefit balance will be reached.
However, these trade-offs will be highly individualized to the
treatment site and the treatment protocol, making it imprac-
tical for this task group to formulate generalized quantitative
optimization procedures.
I.D. Evaluating imaging dose
When analyzing imaging dosimetry during radiation
therapy we must recognize three fundamental distinctions.
The first is between local dose and integral dose. Dose per se
in units of Gy Joules/kg is a local point measure of the
energy deposited per unit of mass by ionizing radiation. Dose
can be reduced only by decreasing the fluence i.e., decreas-
ing the intensity and/or duration of radiation reaching a par-
ticular point at the surface of or within the patient. Integral
dose is the total dose integrated over the exposed mass vol-
ume of the anatomy and can be reduced by either decreasing
the fluence or decreasing the area/volume irradiated. The ef-
fective management of radiological imaging should in the
spirit of ALARA keep both dose and integral dose to a
minimum level.
The second distinction is between planar and axial imag-
ing. In planar imaging the dose to the patient is greatest at
the skin surface nearest to the source and falls off progres-
sively as the radiation transits the body to the image detector.
Axial imaging, which is the basis for CT, differs in that the
dose, by design, is distributed nearly uniformly throughout
the imaged volume to produce 3D images of uniform cross-
sectional quality. Therefore dose in planar imaging is con-
centrated at the skin while dose for tomography is distributed
more in the manner of 3D radiation therapy. Furthermore, the
planar imaging dose has a gradient across organs along the
path from entrance to exit. This distinction is most pro-
nounced for kilovoltage diagnostic modalities where for a
planar image the falloff in dose from entrance to exit can be
a factor of 100 to 1000. Therefore a planar diagnostic imag-
ing modality that delivers 10 mGy of air kerma to the imag-
ing isocenter exposes the patient in a very different way from
a CT scan that delivers 10 mGy of axial air kerma, and the
two quantities should not be casually treated as comparable
or interchangeable. This distinction persists at megavoltage
energies, where a planar portal image distributes dose differ-
ently than a megavoltage CT. Finally, the entrance air kerma
defined for planar radiography does not include backscatter
from the patient, while the generally used CT dose quantity
CT dose index CTDI100, being a measure of internally de-
posited dose in a phantom, does include scatter.
The third distinction is between kilovoltage and mega-
voltage imaging. Absorbed dose is the meaningful quantity
for estimating the biological effects of radiation. At diagnos-
tic imaging energies the range of secondary electrons is short
enough that the tissue kerma and absorbed dose are approxi-
mately the same even at the skin surface. For soft and super-
ficial tissues the conversion factor for tissue to air kerma is
close enough to one to allow use of air kerma in estimates of
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energy of the photon beam increases, though, the range of
the secondary electrons increases. This leads to regions pri-
marily air/tissue interfaces where dose buildup is not in
equilibrium and the local tissue kerma is significantly differ-
ent from the locally absorbed dose. At megavoltage photon
energies neither air nor tissue kerma is a useful indicator of
absorbed dose and thus biological risk at the skin or other
interfaces that are not in electronic equilibrium.
Given these distinctions we must deal with several differ-
ent quantities that are commonly used to report dose. For
varieties of planar kilovoltage imaging we have entrance
skin dose, i.e., air kerma, in units of mGy. Entrance skin dose
does not include backscatter. For kilovoltage CT we have air
kerma on the axis of rotation in mGy, with or without scatter
included, i.e., CTDI in air CTDIair and in a phantom
CTDIw. The use of entrance air kerma for planar imaging
and CTDIw for axial imaging conforms to the AAPM con-
vention for defining reference dose values for diagnostic ra-
diology AAPM Task Group 7 report24. Megavoltage imag-
ing is usually quantified in either monitor units MU or cGy
of absorbed dose. To monitor the integral dose we have the
dose area product DAP for planar imaging and the dose
length product DLP for axial i.e., CT imaging.
There are fundamental differences in the distribution of
radiation from the various imaging modalities used during
radiotherapy, making it difficult to compare and combine the
doses. The prevailing convention for making these compari-
sons involves the conversion of the delivered dose to an
equivalent whole-body exposure that characterizes the result-
ing health detriment.25 The comparison concept is “effective
dose,” defined by Jacobi26 as “the mean absorbed dose from
a uniform whole-body irradiation that results in the same
total radiation detriment as from the non-uniform, partial-
body irradiation in question.” In this context “radiation det-
riment” refers to stochastic risk; effective dose is the stan-
dard metric for estimating stochastic risk. The unit for
effective dose is the milli-Sievert mSv. In theory the effec-
tive dose is defined as in Eq. 1a
E = T wTHT, 1a
where the HT are the average organ doses to tissue T for a
particular exam, and the wT are tissue weighting factors that
represent the relative radiation sensitivities of the organs.
Equation 1a is evaluated for each exam and patient type to
obtain a conversion factor in units of delivered dose. In prac-
tice, effective dose from a particular imaging procedure is
obtained by multiplying the delivered imaging dose, reported
as air kerma, entrance skin exposure, CTDI, absorbed dose,
or MU, by the conversion factor that is specific to the pa-
tient’s age, sex, and the anatomical region that is imaged.
These conversion factors and thus the whole basic concept
of effective dose are based on estimations of stochastic risk
obtained by combining weighted averages of the exposure
risk for all organs in the imaging field of view. To make a
meaningful estimate of risk from the total imaging dose the
contributions from each modality should first be converted to
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will summarize the basic process for converting imaging ex-
posures to effective dose and provide selected example sce-
narios. The evaluation of deterministic risk such as skin in-
jury is more problematic because it occurs at locations where
the absorbed dose from higher-energy imaging photons has
not reached buildup equilibrium.
In discussions of imaging dose management during radio-
therapy one frequently hears the imaging dose compared to
either the direct or concomitant dose delivered by the treat-
ment beam itself. While this comparison is a fundamentally
important consideration it is typically done by naively equat-
ing imaging dose in cGy with treatment beam, scatter, and
leakage expressed also in cGy. In reality the comparison pro-
cess is more complicated. As with the different diagnostic
imaging modalities, the comparison should be made using
units of effective dose. However, as we have already men-
tioned, effective dose is based on estimates of biological ef-
fect integrated over the entire patient volume, which in turn
requires detailed knowledge of the energy spectrum and spa-
tial geometry of the incident radiation. Radiation treatment
geometries are much more varied and patient-specific than
imaging geometries. Furthermore, therapeutic doses and
dose gradients are very different from diagnostic imaging,
which potentially influences the tissue weighting factors used
in computing effective dose. Finally, there is some question
whether the population-based biological effect models used
for risk assessment in diagnostic imaging are appropriate to
the highly selective subset of patients undergoing radiation
therapy.1 For these reasons the estimation of effective dose
during actual treatment, although possible in principle, has
rarely been attempted. Therefore the task group considers
that it is not yet practical to quantitatively combine its evalu-
ation of total imaging dose with the evaluation of total con-
comitant therapeutic dose. Because this comparison appears
to be of great interest to the radiation therapy community, we
consider that theoretical and/or empirical estimates of effec-
tive dose from the therapy beam during treatment should be
made.
I.E. An important note on terminology and units
In this document we use the word “exposure” to describe
the process of delivering radiation as in “the exposure of the
patient to imaging radiation” and the word “dose” for the
amount of radiation received by the patient. We point out this
distinction because in radiological literature there is an old
but not entirely obsolete practice of using the word “expo-
sure” both qualitatively in our sense and also as a quantifi-
able amount of radiation, defined differently than dose. We
never use “exposure” in the sense of a radiation quantity.
The radiation therapy community uses Gy or cGy as the
standard unit for expressing dose, while the diagnostic imag-
ing community uses mGy. Although this document is in-
tended primarily as a resource for radiation therapy, its sub-
ject is imaging dose. Therefore it will follow the diagnostic
imaging convention and express local dose in mGy. Adher-
ing to this convention is especially important when dealing
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that conversion is conventionally given in units of
mSv/mGy cm2. The radiation therapy practitioner is there-
fore cautioned to double check all estimates of imaging dose
for consistency in units, especially when the dose has ini-
tially been expressed in rads or millirads and when portal
imaging doses are being analyzed.
II. IMAGING MODALITIES AND DOSES
Although there is considerable variation among precise
equipment geometries and dose details for imaging modali-
ties used during IGRT, the dose to the patient is still deter-
mined mainly by the required image quality, the attenuation
characteristics of the imaged anatomy, and the imaging duty
cycle rather than the equipment details. Thus for each mo-
dality the dose to the patient for each treatment scenario is
approximately the same regardless of whose equipment is in
use. This allows some generalization from the data available
for particular IGRT setups. For each modality this section
summarizes the standard geometry source/patient/detector
distance, field of exposure, the imaging duty cycle
duration/frequency, and the dose characteristics fluence,
spectra for selected examples of equipment. The following
section discusses the use of this equipment in representative
IGRT applications.
II.A. Portal imaging
Portal imaging has progressed from the use of film as the
imaging detector, through screen/camera imagers and liquid
ionization chambers, to solid-state flat-panel detectors. Al-
though there are institutions still equipped with and using the
older detector systems, the flat-panel imager is emerging as
the new standard detector for portal imaging in IGRT. We
therefore focus our discussion of portal imaging on the use
of solid-state detectors, although it should be understood that
the film systems, being less efficient, require higher doses.
The nominal source/isocenter distance is that of the treat-
ment machine, i.e., 100 cm. Source/detector distances are
variable from 120 to 150 cm. The level of exposure used to
image a particular treatment site is typically varied by inte-
grating dose over multiple acquisition frames of fixed dura-
tion. The duration of each frame is typically fixed as an
integral number of MUs. Cumulative doses to acquire a
single image using amorphous silicon panels range from 1 to
5 MU for most users.
For those LINAC systems that permit the setting of an
arbitrary portal image exposure level i.e., not in integer
number of MU it is possible to acquire images with less
than 1 MU. There are instances where this can provide an
adequate image. Consequently this capability represents an
important means to reduce total portal imaging dose, which
is especially important for scenarios that involve daily imag-
ing.
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Diagnostic x-ray imaging provides better contrast over
shorter exposure intervals than portal imaging and is rapidly
being adopted as an improvement for patient setup and track-
ing during treatment. The usual implementation involves ei-
ther dual kilovoltage x-ray sources and solid-state flat-panel
detectors mounted permanently to the floor and ceiling of the
treatment room or a source/detector system mounted to the
gantry arm for rotation around the patient.
II.B.1. CyberKnife
The CyberKnife Accuray, Sunnyvale, CA is an image-
guided robotic system for radiosurgery and stereotactic ra-
diotherapy. The integrated imaging system determines the
location of the treatment site based on either anatomical or
artificially placed fiducial landmarks and then directs the
LINAC pointing system at the treatment site via a real-time
control loop. It is capable of repeated imaging during treat-
ment. The CyberKnife system utilizes two ceiling-mounted
kilovoltage sources and two floor-mounted amorphous sili-
con flat-panel detectors arranged to provide orthogonal views
on either side of the patient, as shown in Fig. 1. The source-
to-isocenter separation is 265 cm. The isocenter-to-detector
separation is 65 cm. The detector active area is 25 cm
square.
The source/patient entrance distance is nominally 250 cm
for cranial radiosurgery and 240 cm for body radiosurgery.
The source has 2 mm of aluminum filtration and is colli-
mated to a square field that is nominally 17 cm17 cm at
the patient. The source collimator is telescopic, which allows
the field size to be adjusted. Table I summarizes the ranges of
FIG. 1. CyberKnife image-guided radiosurgery system with robot-mounted
linac, patient couch, dual orthogonal imaging detectors in the floor, and dual
x-ray imaging sources mounted at the ceiling. Image courtesy of Accuray,
Inc.
TABLE I. Measured planar radiographic entrance dose levels per image for
the CyberKnife image-guided radiosurgery system.
Site kV mA ms mAs mGy
Cranium and C-spine 105–125 100 100 10 0.25
T-spine 120–125 100–150 100–125 10–20 0.25–0.50
L-spine 120–125 100–200 100–150 10–30 0.25–0.75
Sacrum 120–125 100–300 100–300 10–90 0.25–2.00
Synchrony 120–125 100–300 50–75 5–22.5 0.10–0.50Medical Physics, Vol. 34, No. 10, October 2007technique and approximate entrance dose per image for tar-
gets at various body locations data provided by Accuray,
Inc, Sunnyvale, CA. For the abdominal and pelvic sites the
patient’s body weight strongly influences the technique re-
quired to get good images. The Synchrony technique refers to
a special function of the CyberKnife system that tracks tho-
racic and abdominal treatment sites that move with breath-
ing; the technique for these sites uses a shortened exposure
period to reduce motion blurring. The total exposure for each
target position determination has contributions from two or-
thogonal imaging projections, with a doubling of dose wher-
ever the collimated source fields overlap at the patient.
II.B.2. BrainLab Novalis ExacTrac system
The imaging dose from the radiographic imaging system
ExacTrac that forms part of the BrainLab Novalis patient
positioning system BrainLab, Feldkirchen, Germany has
been measured at the Henry Ford Hospital in Detroit,
Michigan.27 The x-ray imagers are amorphous flat-panel de-
tectors 20.520.5/cm2. As with the CyberKnife, the Nova-
lis system has dual orthogonal x-ray sources and detectors
fixed within the treatment room. This imaging system is con-
figured with x-ray sources in the floor and detectors mounted
at the ceiling, forming an oblique imaging geometry Fig. 2.
The source-isocenter distance is 234 cm, and the isocenter-
detector distance is 128 cm. Table II summarizes the mea-
sured entrance dose levels for two imaging applications—
head and neck targeting and thoracic/lumbar spine targeting.
The sources typically illuminate a 13.513.5 cm2 FOV at
the patient, corresponding to the full FOV of the detectors,
but this is adjustable. All images are obtained in pairs so the
total effective dose is summed from two imaging projections.
FIG. 2. The Brainlab ExacTrac configuration of dual orthogonal x-ray
sources and detectors. Image courtesy of BrainLaB AG.
TABLE II. Measured planar radiographic entrance dose levels for the Brain-
Lab Novalis image-guided radiosurgery system from the Henry Ford Hos-
pital Ref. 27.
Site kV mA ms mAs mGy
Cranium and
C-spine
120 125 100 12.5 0.335
Body 140 125 125 15 0.551
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Both Elekta Stockholm, Sweden and Varian Medical
Systems Palo Alto, CA have introduced gantry-mounted
kV imaging systems Synergy XVI and On-Board Imager
OBI, respectively that can be used in radiographic, fluoro-
scopic, and cone-beam CT modes. When used in radio-
graphic mode to acquire AP and lateral alignment radio-
graphs the dose to the patient is approximately 1–3 mGy per
image,28 depending on technique.
II.C. Computed tomography
CT is and will remain the primary imaging mode for ra-
diotherapy treatment planning29–32 because it displays soft
tissue structures well enough for organ delineation, it reveals
the bony landmarks used for patient setup, it allows for the
generation of DRRs for patient positioning, and it directly
measures the electron densities needed for dose computation
during the planning process. However, as the variety of im-
aging techniques used during image-guided radiotherapy in-
creases, it is easy to overlook the dose from conventional CT.
This oversight is perhaps a carryover from diagnostic imag-
ing practice, which did not fully recognize or appreciate the
exposure levels from CT until the late 1980s.33 When expo-
sure levels from all modes of diagnostic imaging were sur-
veyed it was found that
“CT therefore represents by far the largest contribution
to the radiation exposure of the population from diag-
nostic medical sources.”33
Specifically, although it represents only 4% of all exami-
nations in Germany, it contributes 35% of the total diag-
nostic dose delivered to patients.33
CT can now be performed in axial and spiral mode using
single and multislice fan-beam arrays, and in cone-beam
mode using 2D dimensional detector arrays. In the techno-
logical evolution from single detector/single slice scanners to
spiral, multislice, and cone-beam machines, any reduction in
dose for a single exam achieved via increased speed or effi-
ciency has been more than offset by the resultant tendency
among clinicians to increase the amount of image informa-
tion collected, by increasing the scan length, decreasing the
slice thickness, and/or performing oversampled scans to
monitor fast real-time processes such as breathing. Conse-
quently, CT exposure levels for a particular exam have in
fact tended to increase over the years.33
The tendency in the diagnostic community to exploit tech-
nical advances in CT by expanding the scope and complexity
of its use and thus increasing the resulting exposure has
been mirrored in the radiotherapy community—today, mul-
tiple CTs are acquired to define breathing-related treatment
margins, phase-correlated CT is being introduced to monitor
breathing in real time, CT imaging is being integrated with
treatment machines to allow 3D patient setup using anatomi-
cal landmarks, and repeated scans during the treatment pro-
cess are being considered to adapt treatment plans to changes
in patient anatomy over time.
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index „CTDI…
CT dose depends on the manner in which the scan is
acquired and is most often given as the CTDI in units of
mGy. This is the dosimetric expression used by the AAPM
Task Group 8 report on standardized methods for measuring
diagnostic x-ray doses34 and in the AAPM Task Group 7
report on reference values for radiology.24
The CTDI represents the total dose with or without
scatter—see below deposited at a point within a single scan
slice during a complete exam and allows for the fact that
slices up and downstream from a particular slice will con-
tribute dose to the point in question. It is computed by inte-
grating the dose delivered along the entire axis of rotation
during a single axial rotation of the scanner:
CTDI = l/h
−

Dzdz , 2a
where Dz is the dose at a position z along the axis of
rotation, and h is the nominal slice thickness.
All of the details of dose overlap and summing at a par-
ticular point in space are captured by the quantity CTDI. To
calculate an accurate estimate requires detailed knowledge of
the scanning methodology for a given machine, including
beam collimation, profile, and penumbra, overlapping or
spacing of the slices, spiral versus axial geometry, filtration,
etc. For a factor of 2 or better level of accuracy one should
use tabulated doses for specific exams, such as those given in
Table VII of this report and in references such as Nagel.33
Equation 2a is a theoretical definition of CTDI. For
practical purposes, one uses the measured quantity CTDI100:
CTDI100 = l/h
−50
50
Kairzdz , 2b
where Kair is the air kerma. This is obtained in the clinical
setting with an ionization chamber that integrates the dose of
a single slice of an axial scan over a length of 100 mm.
Measurements are made in the center and at eight equally
spaced peripheral locations around the center circumference
of a cylindrical Plexiglas phantom of either 16 cm head or
32 cm torso diameter. The peripheral measurement points
are at a depth of 1 cm from the surface. CTDIw is the
weighted average of the CTDI100 measurements at the center
and the peripheral locations in the phantom. CTDIw is an
approximation of the average dose of a cross section of a
patient’s body and is calculated as follows:
CTDIw = 2/3CTDI100Periphery + 1/3CTDI100Center .
2c
The measurement of CTDI100 includes backscatter from the
phantom. If the measurement of center axial dose defined in
Eq. 2b is made without a phantom, then one obtains the
axial dose in the absence of scatter dose-free-in-air, or
CTDIair. The axial dose-free-in-air is directly comparable to
entrance air kerma, and has units of mGy.
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of table feed to slice thickness, i.e., the slices do not overlap
or have space between them. If the pitch is less than 1, then
the CTDI does not represent the total effective dose, because
dose at a particular point is superimposed from neighboring
overlapping slices. The general quantity introduced to ac-
count for this superposition or spreading out of dose is the
multiple scan average dose MSAD, which for nonspiral
scans is estimated from the CTDI by
MSAD = nh/ICTDI, 2d
where n is the number of scans i.e., slices, h is the nominal
slice thickness mm, and I is the table advance in millime-
ters during one gantry rotation. For spiral scans at a pitch p,
MSAD is related to the CTDI according to
MSAD = 1/pCTDI. 2e
If dose has been calibrated specifically in terms of weighted
CTDI Eq. 2c then the corresponding MSAD is called ef-
fective CTDI:
CTDIw,eff = MSADw = 1/pCTDIw. 2f
One also sees the quantity denoted “volume CTDI”
CTDIvol, which is the same as CTDIw.
The DLP is an approximation of the dose from an entire
CT examination. DLP is calculated by
DLP = CTDIw Scan Length . 2g
To allow for variability in mAs for any given exam a
normalized nCTDI can be defined in units of mGy per mAs.
The following formula provides a general means to estimate,
within a factor of 2, the delivered axial dose in the absence
of scatter, expressed in units of the mAs technique set up for
a particular examination:
Dair = nCTDIair · QmGy , 2h
where the nCTDIair0.20 mGy per mAs, and Q= current
time per slice in mAs.33 Notice that the product of cur-
rent and time is for one slice, not for the full duration of the
imaging sequence, because the radiation exposure moves
progressively through the anatomy as the patient is scanned.
II.C.2. Doses for typical CT exams
Diederich et al.35 indicate an axial air kerma CTDIair of
30–50 mGy for a typical multislice chest CT of an adult of
average size. Table VII in Sec. IV A 2 provides a more de-
tailed summary of CT doses for a variety of examinations.
II.C.3. Respiration-correlated 4D CT
Modern radiation therapy treatment planning must con-
tend with organ motion during both the CT imaging and
treatment processes. The most problematic source of motion
is due to respiration, which is fast enough to cause artifacts
even in a fast CT. Furthermore, motion must be assessed
prior to treatment to determine either an appropriate motion
margin or parameters for a motion compensation method. To
address both of these problems, respiration-correlated CT
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correlated CT acquires the equivalent of several very fast
CTs over one breathing cycle by actually acquiring a slow,
oversampled CT during which the data are time tagged to
indicate the particular moment in the breathing cycle at
which the measurement is made. After the scan is complete
the time-tagged data are sorted into time bins to reconstruct a
temporal sequence of 3D CT images, each representing a
short interval of the breathing cycle.
There are two basic acquisition methods. One is to make
a single continuous helical scan at a pitch much less than 1
and sort the sinogram data according to physiological signals
or time stamps. The other method is to make an axial scan in
cine mode—i.e., acquire multiple images of a single group of
slices without table motion, while time tagging the recon-
structed slices to correlate with breathing phase, then incre-
ment the table position and acquire another set of multiple
images. In both cases data are acquired for the equivalent of
multiple CT scans, and the dose is consequently greater than
for a single conventional scan.
To maintain standard diagnostic image quality,
respiration-correlated CTs would need to be acquired at the
same technique setting as a conventional single scan, in
which case the total dose for a scan acquired in a single slow
table feed at pitch p1 can be estimated from Eq. 2d.
Keall et al.36 describe the acquisition of 4D thoracic CT data
using the continuous helical method at standard chest tech-
nique with a pitch p=0.125 for which the total effective dose
is eight times the dose from a single conventional scan. In
this scenario the axial air kerma for a respiration-correlated
thoracic CT will be in the range of 250–400 mGy. Low et
al.37 describe a 4D thoracic CT acquisition using the axial
cine method in which 15 time-tagged images, each of 0.50 s
duration, were acquired at each table position at a technique
of 120 keV and 80 mA. This corresponds to 40 mAs per
slice per image. Standard CT technique for an adult chest
scan is in the range of 200–250 mAs per slice. The 4D im-
ages were acquired at a significantly lower technique and
correspond to a total dose approximately equivalent to three
conventional scans, or about 100 mGy.
II.C.4. CT-on-rails
In one approach Primatom Siemens Oncology Care Sys-
tems Group, Concord, CA a conventional CT scanner is
placed in the treatment room, either on the same couch axis
as the LINAC gantry, or on an orthogonal axis to the gantry.
A single couch serves the CT scanner and the beam delivery
system. The couch is first rotated into alignment with the CT
scanner to acquire a pretreatment CT. The CT scanner is
mounted on rails so that it, rather than the couch, moves in
the axial direction relative to the patient to collect a volumet-
ric scan. This CT is used to establish the time-of-treatment
target configuration. The couch is then rotated back into line
with the gantry for treatment. This geometry is illustrated
schematically in Fig. 3.
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An alternative approach is to collect CT images using a
modified conventional treatment gantry. One version of this
is to use the EPID system, or an enhanced detector, for MV
cone beam CT.38 Another variation is to add additional ap-
paratus to generate kilovoltage cone beam CT.39,40 Figure 4
illustrates the generic cone-beam CT geometry for image-
guided radiotherapy. Kilovoltage cone beam CT systems
made by Elekta XVI and Varian On-board Imager both
include a diagnostic kV source and a flat-panel detector,
mounted on opposite sides of the patient and orthogonal to
the LINAC beam. In both systems, the x-ray tube and detec-
tor can retract when not in use to reduce detector exposure to
the detrimental effects of the treatment beam. The integrated
LINAC/CT system unveiled by Siemens Primatom has
been adapted to perform cone beam kVCT as well, but using
an in-line, rather than orthogonal geometry.41 The flat-panel
detector is mounted below the LINAC head in the accessory
tray, and the x-ray source is mounted near the EPID. Kilo-
voltage cone beam CT for radiation therapy has also been
investigated using mobile C-arm gantries. This implementa-
tion is still under study and is not yet commercially avail-
able.
The dose delivered by the Elekta XVI kV cone-beam CT
has been measured by Islam et al.42 The tube was operated at
120 kVp and the complete scan technique was 660 mAs. The
tube energy spectrum was hardened by adding 2 mm of Al
and 0.1 mm of Cu filtration. The detector sensitive area was
41 cm41 cm, and the source/detector distance was
155 cm. Torso and head doses were simulated using 32 cm
diameter and 16 cm diameter cylindrical water phantoms.
FIG. 3. The schematic geometry for a CT-on-rails system showing the two
rotation axes of the couch: C1 being the conventional rotational axis with
respect to the Linac isocenter and C2 being the axis to rotate the couch into
alignment with the CT scanner, which moves on rails along the scan axis.FIG. 4. Conventional geometry for cone-beam CT.
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tom were 16 and 23 mGy, while for the head phantom the
center and surface doses were 30 and 29 mGy, respectively.
These measurements followed the standard CT dose mea-
surement protocol outlined in Sec. II C.
A CBCT pelvic exam dose level of 25 mGy for 400 pro-
jections at 130 kVp and 1.2 mAs per projection has been
reported by Amer et al.43 using the Elekta system. This dose
level is comparable to the measurements of Islam et al.42
when corrected for differences in x-ray technique kVp and
mAs, and scan protocol i.e., number of projections. Coss-
mann et al.44 report doses of 30–80 mGy from the Varian
OBI system for 900 projections, a 48 cm field of view, and a
scan length of 17 cm. Measurements of the Varian OBI sys-
tem at Virginia Commonwealth University using a bowtie
filter, 125 kVp, and the low-dose technique 616 projections
at 0.4 mAs gave center and surface doses of 15 mGy for a
16 cm cylindrical head phantom. For the standard dose
technique 616 projections at 2 mAs the head phantom dose
was 74 mGy at the center and 72 mGy at the surface. Fi-
nally, Endo et al.45 have measured both local and effective
dose for kV CBCT see Sec. IV A 3. All of these measure-
ments are consistent with each other when adjusted for tech-
nique, geometry, and scan protocol i.e., number of projec-
tions.
II.C.6. Mega-voltage CT
Another option for on-line CT imaging is to use the MV
linear accelerator as the radiation source, rather than adding a
diagnostic x-ray tube. A number of research MVCT systems
have been developed, of which one of the earliest to be used
clinically is the system at the University of Tokyo,46 which
uses a cadmium tungstate detector for improved efficiency. It
collects complete 3D images in approximately 38 s in a fan-
beam scan mode at doses of 14 to 28 mGy and has a reso-
lution of 3.5 mm. Beam energy is 6 MV. This system has
been used for patient setup/repositioning and real-time beam
monitoring during stereotactic radiosurgery.
An MVCT system was also developed as part of the Uni-
versity of Wisconsin TomoTherapy project, and has since
been commercialized as part of the Hi-Art® system by To-
moTherapy, Inc. Madison, WI. This integrated system is
based upon a CT gantry and can operate in both a therapeutic
and MVCT imaging mode. The MVCT uses a 738 channel
xenon CT detector that is approximately 20% efficient at MV
energies. The scan time is currently 5 s per slice. The total
imaging dose depends upon the scan protocol e.g., pitch,
slice thickness, dose rate, etc. and the patient size, but
among the 28 centers clinically treating with TomoTherapy,
the typical range is between 10 and 30 mGy. This dose
shows contrast of 2%–3% and resolution of 1.4 mm. For
comparison, diagnostic CT typically has spatial resolution of
about 0.75–1.0 mm at high contrast and resolution of a few
millimeters at 0.5% contrast.33,47 The scan range of the
MVCT is selectable to cover as much or as little of the
tumor/anatomy as necessary for setup and registration.
4051 Murphy et al.: Imaging dose during image-guided radiotherapy 4051Cone beam MVCT has been implemented clinically at the
University of California, San Francisco, in partnership with
Siemens Medical,38 and at the Memorial Sloan-Kettering
Cancer Center MSKCC, in collaboration with Varian Medi-
cal Systems. Both of these systems are based on conven-
tional linacs. The MSKCC system can obtain an MV cone-
beam CT of the thorax suitable for tumor delineation from
100 projections using a total of 20 MU of radiation.48 Low-
dose cone-beam MVCT is complicated by variations in beam
flatness, symmetry, and other characteristics when the
LINAC is operated at low output. In each case, continuing
investigations are being made into more efficient detector
technologies to reduce dose and improve image quality.
II.D. Fluoroscopy
Fluoroscopy is the most used imaging technique during
image-guided surgical interventions. Its use in radiation
therapy has been mainly in a similar vein, for surgical guid-
ance assistance during brachytherapy seed insertion, but it is
also entering wider use to monitor anatomical movement be-
fore and during external beam radiotherapy.
II.D.1. C-arm fluoroscopy
Fluoroscopy requires the continuous or near-continuous
delivery of x-ray flux to obtain a real-time radiographic
record of changing anatomy. Typical fluoroscopic units such
as C-arms with x-ray image intensifiers will automatically
adjust the kV/mA technique to obtain acceptable images. The
automatic settings compensate for the total attenuation
through the patient in order to maintain an adequate signal-
to-noise at the image intensifier and thus will vary widely
from site to site and according to the patient’s weight. Fur-
thermore, different C-arms can have different sensitivity lev-
els, and the functioning of the individual systems can be
variable due to quality control and system calibration, etc.
This results in a spread of dose levels for any particular
exam.
There have been numerous surveys of typical or routine
exposure levels for C-arm fluoroscopy that include ranges
around the mean exposure level. The 2002 Nationwide
Evaluation of X-ray Trends NEXT survey of x-ray exams
reported a median entrance dose rate EER of
22±14 mGy/min for mobile C-arm units imaging a phantom
equivalent to 21.5 cm of water 30 cm above the image inten-
sifier USFDA Nationwide Evaluation of X-ray Trends
NEXT49. This would be the average dose rate for an ab-
dominal fluoroscopic exam, with somewhat less dose for a
thoracic exam. Therefore, for pretreatment fluoroscopic stud-
ies of thoracic and abdominal organ motion the typical en-
trance dose to the patient will be within a factor of 2 ap-
proximately 20 mGy/min.
The typical source-detector distance for a C-arm is ap-
proximately 100 cm. With an adult patient in the field of
view this creates a tight geometry in which the entrance skin
dose can change dramatically if any part of the patient moves
closer to or further from the source. Moving the C-arm by
only a small amount during the procedure can risk serious
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patient at all times during the imaging procedure.
II.D.2. Varian on-board imager „OBI… and Elekta
synergy XVI
Both the Varian OBI and Elekta XVI CBCT systems can
operate in fluoroscopic mode. The Elekta system has a
source/isocenter distance of 100 cm and a combination of
2 mm Al and 0.1 mm Cu filtration at the tube. Islam et al.42
have measured the dose rate delivered by the Elekta system
in fluoroscopic mode to be 0.06 mGy/mAs at 100 kVp and
0.1 mGy/mAs at 120 kVp. This is the dose at the surface of
a 16 cm diameter cylindrical head phantom. For a technique
of 100 kVp, 25 mA, and 4 ms exposure per frame50 this
would correspond to a fluoroscopic dose rate of
10.8 mGy/min. This is about 12 the dose rate of a typical
C-arm see Sec. II D 1 and a little more than the entrance
skin dose rate measured for the Hokkaido fluoroscopic sys-
tem see Sec. II D 3 and Table I. However, if the Hokkaido
system were to be run at the same equivalent technique for
the 1/r2 difference in geometries, it would deliver about 1.8
times as much dose.
II.D.3. Dedicated in-room fluoroscopy
A technique of dual-view fluoroscopy for tumor tracking
during radiotherapy has been developed at the Hokkaido
University School of Medicine. The imaging system consists
of four diagnostic x-ray sources and four x-ray image inten-
sifier units configured around the treatment isocenter as
shown in Fig. 5. The rectangular x-ray field at the patient is
14 cm19 cm. The source/isocenter distance is 280 cm, and
the isocenter/detector distance is 180 cm.11 During each
treatment fraction, two of the four imaging systems are used
to locate and continuously track radio-opaque artificial fidu-
cials implanted at the treatment site.51 The image data from
the two views are combined to obtain precise 3D trajectories
of the treatment site.52,53 A particular pair of imaging systems
can be selected to avoid interference by the gantry and
LINAC in the imaging lines of sight. Each imaging system
acquires 30 frames per second using a nominal exposure
time of either 2 or 4 ms per frame. The exposure level and
detector sensitivity are sufficient to observe fiducial markers
in the lung, in the liver, and in the pelvis.54,55
Table III summarizes the air kerma measured at the iso-
center for each of the imaging techniques used during
treatment.56 For lung and liver tracking the technique uses
80–125 kV, 80 mA, and either 2 or 4 ms exposure duration
per frame. These are nominal exposure times—high-voltage
x-ray tubes do not switch on and off instantaneously. Be-
cause the patient’s skin surface is typically closer to the
source, resulting in a higher dose, the data of Table I have
also been scaled by 1/r2 to estimate the entrance skin dose
when the patient’s skin surface is displaced by 5 cm, or
30 cm, from the isocenter towards the source. Treatment is
always done with two diagnostic beam viewpoints, so wher-
ever the two imaging beams overlap the total skin dose is
twice the dose in Table III.
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III.A. Planning
Because of the special utility of the CT Hounsfield num-
ber in treatment planning, x-ray CT will remain the primary
imaging modality for radiotherapy planning for the foresee-
able future. Conventional planning requires one axial or spi-
ral CT assuming a motionless patient. When imaging treat-
ment sites that move during breathing, motion artifacts can
be reduced using respiration-correlated CT. This procedure
involves acquiring an oversampled CT data set that is time
stamped so that the data can be sorted into time bins corre-
sponding to discrete moments of the breathing cycle see
Sec. II C 3.
Cone-beam CT is currently under development and can
potentially be used for pretreatment planning as with the
TABLE III. Entrance air kerma at the patient from the Hokkaido fluoroscopic
tracking system for an exposure period of 60 s at 30 image frames per
second.
Air kerma @ Patient mGy
kV mA ms @Isocenter
5 cm from
Isocenter
30 cm from
Isocenter
60 80 2 1.11 1.14 1.38
4 2.07 2.15 2.60
80 80 2 2.45 2.54 3.07
4 4.28 4.44 5.37
100 80 2 4.35 4.51 5.46
4 7.41 7.68 9.30
120 80 2 6.69 6.94 8.39
4 10.90 11.30 13.67Medical Physics, Vol. 34, No. 10, October 2007Varian Acuity system. However, it is subject to cupping ar-
tifacts and inaccuracies in the Hounsfield number due to its
significantly higher scatter-to-primary-fluence ratio.57 These
inaccuracies can affect the accuracy of the electron densities
that are used for dose calculation. Charge trapping and in-
complete readout in the solid-state imaging panel image lag
can also make it susceptible to streaking and blurring arti-
facts that do not arise in fan-beam CT.57 Consequently the
primary use at present is for in-room setup see Sec. III E 3.
Megavoltage CT has less contrast than kV CT but it also
has less streaking artifact due to high-Z materials. Further-
more the reconstructed Hounsfield numbers more closely
represent the attenuating electron densities seen by the treat-
ment beam, making it useful to the dose calculation compo-
nent of the treatment planning process.
III.B. Pretreatment fluoroscopy for motion estimation
Modern techniques to deal with intrafraction organ mo-
tion due to respiration are aimed at managing the motion
rather than accommodating it via large planning margins.
There are three basic approaches to the management prob-
lem: 1 reduction of the motion via breathholding,58–61 ac-
tive breathing control,62 or assisted ventilation;63 2 tempo-
ral tracking by detecting the breathing phase and gating the
beam on and off synchronously with the breathing cycled;64
3 spatial tracking by detecting the tumor position and shift-
ing the alignment of the beam synchronously.65 All three
techniques require a pretreatment assessment of the motion
to define parameters for its management. Respiration-
correlated 4D CT provides one means to analyze the motion
over a short time interval e.g., a few breathing cycles, but
FIG. 5. Fluoroscopic tracking system
at Hokkaido University.the motion is sufficiently complex that longer periods of ob-
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with fluoroscopic imaging for periods ranging from 30 s to
several minutes.2 The imaging dose delivered during a 5 min
fluoroscopic study can exceed 100 mGy and must be in-
cluded in the overall imaging dose budget for the patient.
III.C. Brachytherapy guidance
Diagnostic imaging to support brachytherapy can involve
CT, film-based radiography, C-arm fluoroscopy operated in
continuous or single-frame mode, and simulators.66 There are
a number of different diagnostic imaging scenarios to sup-
port brachytherapy, depending on the procedure. There is
also considerable variability among different institutions. For
example, tandem and ovoid procedures involve either a
whole-pelvis CT or orthogonal films for each fraction. Most
practitioners in LDR for prostate implants use fluoroscopy
continuous or single-frame mode during the procedure and
a followup CT after the implant in some institutions on day
1; in other institutions on day 30. In prostate HDR fluoros-
copy is again used during the catheter implantation; this is
repeated for fractionated treatments. If prostate HDR is com-
bined with external-beam radiotherapy, a CT study will also
be acquired. Endometrial and cervical HDR include films for
every fraction. The MammoSite procedure is typically
guided by an evaluation CT, multiple CTs during placement,
and films for each fraction, although some institutions have
replaced the films with ultrasonography.
III.D. Simulation
Simulation refers to the acquisition of reference setup im-
ages to which the in-room setup images are compared to
determine how close the target is to the planned position.
Historically these images were acquired after the CT study in
a separate pretreatment procedure using a kV imaging sys-
tem that approximately reproduced the patient’s position in
the planning CT. This therefore added one or two planar
diagnostic-quality kV images to the total imaging budget.
For a film-screen-simulation system, and assuming 400 film
speed and 125 kVp, the typical chest simulation would re-
quire 0.025 mSv for AP and 0.075 mVs for lateral.33
With the advent of fast beam’s-eye-view DRR computa-
tion the reference images can now be obtained directly from
the planning CT virtual or CT simulation, thus eliminating
the additional imaging dose while improving the accuracy of
the patient setup process. This advance in image-guided ra-
diotherapy is one of the rare instances in which the imaging
dose has been reduced while increasing the treatment accu-
racy.
III.E. Interfraction setup
After CT-based planning, the most common use of imag-
ing during radiotherapy is patient setup at the beginning of
the fraction. This was initially done with megavoltage portal
imaging but now can also be done with in-room planar kV
imaging, or in-room CT. For 3D setup it requires one or
more pairs of orthogonal images.
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Several types of fractionated schedules are followed for
portal imaging.67 The most conservative is weekly acquisi-
tion of images, which is appropriate for treatment plans that
are not highly conformal. More precise targeting is enabled
by taking portal images daily for a week to assess tumor
position variability and systematic setup error, followed by
weekly imaging after correction for systematic offsets.
Highly conformal techniques can call for daily imaging.68
The advent of solid-state portal detector systems, which are
more efficient than film systems and thus require less dose,
has encouraged more frequent imaging schedules.
For each schedule there are several imaging scenarios.
The crudest is a single AP image for 2D positioning. Three-
dimensional positioning requires two images, which by con-
vention are anterior/posterior AP and lateral. These view-
points were inherited from diagnostic imaging conventions
and are not optimal for 3D position estimation—the AP im-
age quality is always much better than the lateral quality.
Two oblique viewpoints can provide better position recon-
struction cf. Figs. 1, 2, and 5. As Table IX in Sec. IV A 3
shows, the effective dose from the exposure depends on
viewpoint. Some setup procedures involve a double exposure
technique for each viewpoint. Finally, highly conformal
treatments sometimes include a second set of portal images
at the end of the fraction to fully document the patient’s
position. Therefore the most meticulous and conformal setup
procedure could involve daily dual-view double exposures
followed by end-of-fraction verification imaging. This adds
up to 180 portal images for a thirty-fraction treatment.
III.E.2. In-room kV radiography
In-room kV imaging systems replace the function of the
EPID for setup based on dense radiographic landmarks such
as bone and implanted fiducials. It almost always involves
taking dual orthogonal images at either traditional AP/lateral
viewpoints or oblique angles cf. Figs. 1, 2, and 5. The setup
procedure can involve one, two, or more pairs of images,
depending on the criteria for targeting precision. For highly
precise targeting, as required by radiosurgery for example,
the first image pair indicates a coarse setup correction, fol-
lowed by a second image pair to verify and/or provide a
further fine position correction, sometimes followed by an-
other image pair to verify final positioning. The gantry-
mounted Varian OBI can be used in this capacity.28
III.E.3. In-room CT
In-room planar radiography is useful for setup guided by
either bony landmarks or implanted fiducials but is of limited
use in assessing soft tissue position and shape. In-room CT
has been developed to assist soft-tissue target alignment be-
fore the start of treatment.69 In one approach a conventional
CT scanner is placed in the treatment room on the same
couch axis as the LINAC gantry. A single couch serves the
CT scanner and the beam delivery system see CT-on-rails,
Sec. II C 4. Another approach uses a kV source and diag-
nostic detector mounted to the treatment gantry at 90° with
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voltage cone-beam CT. A third approach uses the treatment
beam and a gantry-mounted EPID to obtain a megavoltage
cone-beam CT. TomoTherapy uses an MV linac rotating in a
CT-like gantry to obtain megavoltage CT in a fan-beam scan
mode.
Regardless of how in-room CT images are collected, the
most common application for them at present is patient setup
verification and repositioning. In this process, the imaging
system is used to collect a CT volume of the patient imme-
diately prior to treatment. While most systems have the tech-
nical ability to offer improved image quality at higher doses,
or noisier images at lower doses, it is nonetheless common at
present for most to maintain CTDIw or its cone-beam coun-
terpart in the 10–50 mGy range. Once the images are col-
lected, tools are usually provided for manual or automatic
image registration, and an ability to conveniently reposition
either the patient or therapy beam in the treatment room.
Beyond registration and repositioning, there are numerous
more advanced applications for in-room CT images. These
concepts are broadly categorized as adaptive therapy or the
use of feedback in improving patient treatments. Examples
of adaptive therapy include modifying contours or plans to
account for anatomical changes, dose reconstruction, and
image/dose deformation.
III.F. Intrafraction monitoring
Intrafraction imaging is important for situations where the
target can move significantly or where the precision require-
ments are strict enough to warrant constant surveillance of
the target during irradiation e.g., frameless radiosurgery.
The image data can be used as a passive record of target
position, or to gate the beam, or to adjust the beam alignment
with the target. However, to use the image data to actively
maintain beam alignment, it must be possible to realign the
beam with the patient automatically during treatment by
moving either the linac or the patient. Presently, the Cy-
berKnife is the only commercial radiotherapy system with
this capability.
III.F.1. kV Radiography
The BrainLab ExacTrac system is capable in principle of
acquiring radiographs during the treatment fraction both be-
tween and during beams although scatter from the treatment
beam into the kV imaging panels will degrade image quality,
and presently there is no capability to automatically realign
the patient in response to changes in target position. Like-
wise, the Varian OBI and Elekta systems could in principle
provide intrafraction radiography, although their gantry
mounting restricts them to a single 2D viewpoint at a time
and requires a more sophisticated technique for image regis-
tration as the imaging viewpoint moves during treatment.
The CyberKnife imaging system is presently the only
commercial system used for initial patient positioning fol-
lowed by periodic position remeasurement during the frac-
tion. After each new measurement a robotic manipulator
moves the beam to the newly detected target position. The
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hypofractionated radiotherapy 2–5 fractions. Typical imag-
ing frequency is 30–50 image pairs per fraction 1–2 acqui-
sitions per minute but it can be increased to provide images
every few seconds or decreased to provide only setup and
position verification data. The imaging duty cycle for any
particular patient is usually adapted to the frequency and
magnitude of patient movement detected during treatment.
In typical cranial radiosurgical treatments, the entire treat-
ment dose is delivered in one fraction while approximately
30 image pairs are taken at 30–60 s intervals to track target
position.70 This results in a total entrance dose in air of
7.5 mGy. Spine treatments are typically divided into three
fractions with 20–40 image pair acquisitions per fraction,70
for a total average entrance dose in air ranging from a mini-
mum of 22.5 mGy for the C-spine to a maximum of
200 mGy for the sacrum.
III.F.2. kV Fluoroscopy
Fluoroscopic monitoring of the treatment site is being
used at Hokkaido University to gate the therapy beam.11 The
prototype Hokkaido system operates in pulsed fluoroscopic
mode, acquiring 30 frames per second with either 2 or 4 ms
exposures. Images are acquired continuously during the
treatment irradiation. To reduce the amount of dose from
fluoroscopy, the pulse rate is changeable from 30 to 15, 10,
5, and 2 frames in the second-generation system.71 The po-
sition of the patient couch can be adjusted using an on-line
remote control unit at the console of the LINAC outside of
the treatment room. Ten systems in eight hospitals are ac-
tively used in Japan but the machine is not commercially
available at present.
III.F.3. MV-EPID cine mode imaging
It is possible to acquire portal images continually during
the fraction for passive monitoring of patient position. In this
mode the EPID images are acquired continuously without a
trigger from the linac. For example, the Varian AS500 EPID
Varian Medical Systems is capable of operating in cine
mode at approximately one frame every 1.6 s. This imaging
mode has the distinction of being the only approach that uses
the actual therapy radiation rather than an open field and
thus adds no extra dose.
IV. DOSE EVALUATION
The AAPM Task Group on Reference Values for Diagnos-
tic Radiography takes the position that clinicians should not
be held to strictly defined limits on radiographic exposure to
patients but should be aware that, when their exams signifi-
cantly exceed a typical or reference dose level as represented
by an agreed upon “reference value” for that category of
exam, the clinician should take steps to reduce the exposure
levels.24
The data tabulated for all of the imaging procedures used
in image-guided radiotherapy show that a typical image-
guided treatment scenario involving a 4D CT and intrafrac-
tion motion tracking will involve doses that are 10 to 100
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part of the anatomy.24 This underscores the fact that IGRT
presents an entirely different situation in radiographic expo-
sure and that the diagnostic reference values are not relevant.
The IGRT imaging dose can be divided into four categories:
1 kilovoltage skin dose, 2 kilovoltage organ dose, 3
megavoltage skin, and 4 megavoltage organ dose.
The U.S. Food and Drug Administration has issued an
advisory on the skin injury risks associated with complex
image-guided interventional procedures that can involve
long exposures to fluoroscopy and other diagnostic imaging
x-ray procedures. The National Cancer Institute has also re-
cently published an advisory on the risks associated with
interventional fluoroscopy.72 These advisories note the fol-
lowing approximate threshold dose levels at which eye and
skin injuries of increasing severity can occur,12,72 based on
evidence accumulated following a variety of fluoroscopically
guided interventions:
Effects Threshold Time of Onset
Early transient erythema 2000 mGy 2–24 h
Temporary epilation 3000 mGy 1.5 weeks
Main erythema 6000 mGy 3 weeks
Permanent epilation 7000 mGy 3 weeks
Dermal necrosis 15,000 mGy 52 weeks
Eye lens opacity detectable 1000 mGy 5 years
Cataract debilitating 5000 mGy 5 years
These observations are based on a wide range of imaging
scenarios, including procedures performed in one long ses-
sion and procedures repeated many times over several
weeks, making it difficult to establish the significance of the
time period over which the dose is delivered. By way of
comparison, an IGRT treatment involving a 4D planning CT,
5 min of pretreatment fluoroscopy to assess tumor motion,
followed by thirty fractions of fluoroscopically guided radia-
tion therapy 2 min per fraction, ending with a follow-up
CT can result in a total skin dose exceeding 1500 mGy.
Daily CT for patient setup can add 1000 mGy of both skin
and organ dose. Although the imaging dose in interventional
fluoroscopy is typically delivered over a much more com-
pressed time scale than in conventional IGRT, which might
be a factor influencing the injury thresholds, it should be
recognized that in the most aggressive applications of IGRT
the concomitant imaging exposure can approach levels at
which deterministic injury might be a potential outcome.
Imaging dose during radiotherapy is often discussed in
relation to the total therapeutic dose to the target and/or the
concomitant background and scatter dose from the beam,
expressed in cGy. This direct comparison is inappropriate
and misleading because of the varying biological effects as-
sociated with different dose delivery scenarios. To provide an
approximate basis for comparison of imaging dose to therapy
dose we must convert all the doses to a common unit of
radiobiological effect—namely the effective dose. The con-
version process depends on how the radiation is distributed
through the anatomy, how it deposits energy locally, and how
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tablished procedures for converting different imaging doses
to effective dose, but, as mentioned earlier, little has been
done to study the conversion of therapeutic dose into effec-
tive dose. The main difficulty in analyzing effective thera-
peutic dose is the fact that, while imaging procedures tend to
follow standardized scenarios, therapeutic irradiation is pa-
tient specific. Furthermore, Aird1 points out that the special
health characteristics of the patient subgroup undergoing
therapy will bias the evaluation of biological effect underly-
ing the concept of effective dose. We note, however, that
this same circumstance can also bias the calculation of effec-
tive diagnostic imaging doses. Therefore this report is lim-
ited to a discussion of how to compile diverse imaging doses
into a total effective imaging dose.
IV.A. Conversion of imaging dose to effective dose
The only dose quantity that allows any intercomparison of
stochastic risk between the different imaging scenarios de-
scribed in this report is effective dose, which combines the
quality and distribution of radiation throughout the body
with its effect on a number of specific organs. It is distin-
guished from equivalent dose, which is a local measure of
biological effect obtained by multiplying local absorbed dose
at a point in a specific organ by a biological weighting factor.
Effective dose is computed by weighting the equivalent dose
values for various organs by the organ weighting factors and
then summing over the exposed volume so as to obtain an
equivalent whole-body dose. It is therefore actually an ex-
pression of integral dose rather than local dose deposition.
The precise effective dose depends on the imaging modality,
the energy of the radiation, the age and sex of the patient,
and the anatomical particulars of the exam. The effective
dose is obtained from the absorbed dose D mGy via a
semiempirical conversion factor F mSv per mGy such that
E = D · FmSv/mGy . 3a
The quality factor F has been tabulated for different exam
types. It can be expressed in terms of dose-to-air i.e., ab-
sorbed dose measured with an ionization chamber in a phan-
tom, with scatter included or dose-free-in-air i.e., dose-to-
air without a phantom and thus with no scatter. This
distinction is important when analyzing CT doses.
Converting the megavoltage x-ray dose from portal imag-
ing, expressed in MU or cGy, into effective dose presents
some special difficulties that make the conversion more dif-
ficult than for diagnostic imaging. These difficulties include
the difference between air kerma and absorbed dose in re-
gions of nonequilibrium such as the skin and air/organ in-
terfaces and the differences in dose intensity and gradient
noted in Sec. I D. Nevertheless, it is possible to make some
useful approximate evaluations of megavoltage imaging dose
for general comparison to diagnostic imaging dose.
IV.A.1. kV Planar imaging
The effective dose for planar projection radiography ismost directly obtained from the dose-area product entrance



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computed a table of conversion factors for AP and lateral
radiographs of different anatomical sites as a function of
x-ray energy spectrum, organized by tube voltage and filtra-
tion thickness. A subset of these conversion factors is pre-
sented in Tables IV and V.
As an example, we calculate the conversion factor from
entrance dose mGy to effective dose mSv for AP projec-
tions of the chest using a circularly collimated field 25 cm in
diameter at the patient. For 80 kVp and 2 mm of filtration,
we multiply 21.510−5 mSv/mGy cm2 by the 491 cm2 area
of the exposed surface of the patient to get the conversion
coefficient of 0.11 mSv/mGy.
IV.A.2. kV Fan-beam CT
Because CT, unlike planar radiography, delivers a uniform
amount of radiation throughout the imaged volume, its bio-
logical impact on individual organs differs significantly from
the dose from planar imaging. Furthermore, the internal dose
from CT is orders of magnitude higher than for planar radi-
ography. Therefore to make a meaningful comparison be-
tween planar and CT dose, one must convert CTDIair to ef-
fective dose. This conversion must account for variations in
biological effect to different organs and additional factors to
accommodate scan length, beam quality, etc. All of these
effects combine into a conversion factor F mSv/mGy to
give an effective dose for comparison to other radiographic
procedures:
TABLE IV. Conversion coefficients to give effective dose mSv from dose-
area product of entrance skin dose mGy cm2 for AP projections. The total
filtration is in millimeters of aluminum. All conversion coefficients are
mSv/mGy cm210−5.
kVp
Filter
mm Al
Head
10−5
Chest
10−5
Lumbar
Spine 10−5
Abdomen
10−5
Pelvis
10−5
80 2 3.0 21.5 18.9 16.8 20.0
4 4.1 26.9 24.9 22.2 25.2
100 2 4.1 25.5 24.0 21.5 24.3
4 5.3 31.0 30.2 27.2 29.6
120 2 4.9 28.9 28.0 25.2 27.7
4 6.1 33.9 33.8 30.5 32.6
TABLE V. Conversion coefficients to give effective dose mSv from dose-
area product of entrance skin dose mGy cm2 for lateral projections. The
total filtration is in millimeters of aluminum. Conversion coefficients are
mSv/mGy cm210−5.
kVp
Filter
mm Al
Head
10−5
Chest
10−5
Lumbar
Spine 10−5
80 2 2.9 8.3 8.1
4 4.0 10.9 11.0
100 2 3.9 10.6 11.0
4 5.0 13.3 14.2
120 2 4.7 12.5 13.5
4 5.8 15.0 16.7Medical Physics, Vol. 34, No. 10, October 2007E = CTDIair · FmSv/mGy . 3b
A detailed evaluation of the overall conversion factor F
depends on the scan length and is therefore developed by
summing contributions along the length of the scan using a
factor fz per 1 cm of slice thickness. Examples of the con-
version factor per unit length fz and the composite conver-
sion factor F for different patient characteristics and organs
can be found in Nagel.33 Table VI summarizes typical doses
in air, effective dose conversion factors, and effective doses
for several exam types.
Table VII was generated using data collected all over Eu-
rope for dual and multiple CT scanners. It is an excerpt of
data for the years 2000 and 2002 from the original table
published by Friberg.75
IV.A.3. kV Cone-beam CT
Endo et al.45 have made dosimetry measurements for a
kilovoltage cone-beam CT system that utilized a 45 cm
60 cm fluorescent screen coupled to a lensed CCD image
intensifier. The imaging plane was oriented such that its long
axis was parallel to the patient’s cranial/caudal axis. They
measured mean and maximum entrance skin dose as well as
organ dose, from which they calculated effective doses for a
head and a chest exam. The results are summarized in Table
VIII. The effective dose conversion factor effective dose
divided by mean skin dose, divided by detector area of 6
10−5 mSv/mGy cm2 for cone-beam head exams is about
25% greater than the factor for planar diagnostic head exams
Tables IV and V. The cone-beam conversion factor for a
chest exam is about 25% less than for planar diagnostic im-
aging. When compared to fan-beam CT, the cone-beam con-
TABLE VI. Typical values of the conversion factor F from CTDIair in mGy
to effective dose E in mSv for adult patients for recent routine CT exams
in Germany Ref. 74.
Examination
Scan Length
cm Pitch Factor F
CTDIair
mGy E mSv
Head 12.0 1.0 0.023 81 1.9
C-spine 18.0 1.2 0.044 55 2.4
Chest 27.0 1.3 0.136 47 6.4
Abdomen 42.0 1.3 0.239 54 12.9
L-spine 6.0 1.1 0.029 100 2.9
Pelvis male 24 1.2 0.137 60 8.2
TABLE VII. Mean Values of the effective dose E, CTDIvol, and DLP Ref.
75.
Examination Period yr
E min–max
mSv
CTDIvol min–
max mGy
DLP min–max
mGy cm
Head 2002 2.2 1.3–3.7 79 45–116 991 590–1626
Chest 2002 5.8 1.8–11.3 10 4–17 317 102–647
Abdomen 2002 11.4 7.4–14.7 12 8–19 643 389–847
LS 2000 4.3 2.3–9.3 34 19–54 265 165–396
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higher for the head, when corrected for scan length and axial
pitch.
The measurements by Islam et al.42 for the Elekta kV
cone-beam system are given in Table IX. Note that because
the detector’s longitudinal dimension is less than the system
measured by Endo,45 the DLP and consequently the effective
dose are less as well.
IV.A.4. Portal imaging
The dose from portal imaging contributes direct dose to
the target volume and concomitant exposure elsewhere, with
an additional component of direct dose outside the target
cross section due to the uncollimated/unblocked field of ex-
posure. The direct target dose should be included in the
planned therapeutic dose. Waddington and MacKenzie68
have made an approximate conversion of portal imaging
dose to effective dose for various treatment sites. This evalu-
ation is based on the anatomy of an adult of average height
and weight. Because effective dose is calculated from the
distribution of radiation among organs of variable risk, it will
vary from patient to patient, but the average scenario pre-
sented here should suffice for a factor of 2 level of accuracy.
Table X summarizes the results of Waddington and MacK-
enzie for a 6 MV extended field 18 cm15.6 cm at an
SSD=88 cm.
IV.A.5. MV cone-beam imaging
MV cone-beam imaging is practiced only at a small and
select number of facilities. We are unaware of any systematic
evaluation of its effective dose. However, MV radiation has a
relatively small attenuation gradient through the anatomy, in
contrast to the steep gradient for diagnostic energy radiation.
Therefore we assume that, to a first approximation, the ef-
fective dose for MV cone-beam imaging can be estimated by
summing the individual doses from each gantry angle using
for each projection the portal imaging conversion factor of
Table X for the examination site. There has not been a pub-
lished report on effective dose calculated directly for MV
TABLE VIII. Dose from kV cone-beam CT Ref. 45.
Parameter Head Chest
Maximum skin dose mGy 100.5 85.4
Mean skin dose mGy 68.5 57.0
Effective dose mSv 10.9 24.6
Conversion factor mSv/mGy cm2 6.010−5 16.010−5
TABLE IX. Dose from the Elekta XVI kV cone-beam CT Ref. 42.
Parameter Head Chest
Mean dose at center mGy 29 16
Mean skin dose mGy 30 23
Effective dose mSv 3.0 8.1
Conversion factor mSv/mGy cm2 6.010−5 16.010−5Medical Physics, Vol. 34, No. 10, October 2007cone-beam CT, so the assumption here is that the field of
view for a single projection in MV CBCT is comparable to
an open-field portal image. Because of the difference be-
tween AP and lateral doses, the summation should be an
AP/lateral average weighted by the angular position of each
image acquisition.
IV.B. Examples of cumulative imaging dose and
stochastic risk
The most recent ICRP coefficient for estimating the life-
time probability of inducing a fatal cancer from a single ra-
diographic exposure is 510−5 per mSv of effective dose.76
This coefficient is based on the linear no-threshold model of
radiation risk and is derived primarily from studies of atomic
bomb survivors. For image-guided radiotherapy the estimate
is overly simplistic, as it neglects details such as the time
period over which the dose is delivered, as well as the age
and sex of the patient, i.e., how does one handle the differ-
ence between a single CT and a sequence of portal images
taken over many days? Nevertheless it provides a starting
point to evaluate the added risk from imaging exposures dur-
ing radiotherapy. We use this simple estimate in the follow-
ing examples of image-guided radiotherapy scenarios.
Consider a prostate treatment routine that involves a con-
ventional fan-beam CT for planning 60 mGy, 8.2 mSv,
from Table VI followed by 30 daily portal image pairs at 2
MU each 301.3 mSv, from Table X. This delivers a total
effective imaging dose of 47.2 mSv. Using the ICRP-6076
coefficient of 510−5 there is an estimated probability of
0.2% of radiation-induced cancer in the patient’s lifetime.
For a 70 year old this might be considered an inconsequen-
tial risk.
As a second example, consider a 30 year old female being
treated for cervical cancer. If that patient undergoes 30 com-
plete daily in-room CTs for targeting and compensation of
organ deformation 308.2 mSv, from Table VI, she re-
ceives an estimated 246 mSv of effective dose, resulting in a
1.2% probability of a radiation-induced cancer. However, we
note from Table X that the female pelvis is more radiation
sensitive than the male pelvis where the gonads can be
TABLE X. Effective dose E from 6 MV portal images 18 cm15.6 cm
taken at SSD=88 cm Ref. 68.
Port View Gender
Effective Dose E
mSv/MU
AP pelvis Male 0.34
Female 0.52
Lat pelvis Male 0.32
Female 0.7
AP chest Male 1.74
Female 1.8
Lat chest Male 2.56
Female 2.23
Lat neck N.A. 0.12shielded, so this risk estimate is likely to be low.
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cancer risk in patients that already have cancer, it remains
true that some of the added risk is negotiable, in the sense
that added imaging can improve the therapeutic ratio for the
primary disease. The risk/benefit trade becomes more com-
plex when one considers that many radiotherapy procedures
address noncancerous diseases. For example, radiosurgery is
commonly used to treat arteriovenous malformations
AVMs,77,78 acoustic neuromas,79 trigeminal neuralgia,80
and pituitary adenoma.81–83 The advent of frameless image-
guided radiosurgery adds imaging dose to the concomitant
dose from the therapy beam, increasing the risk of inducing a
primary cancer.
For a third case we use the Hokkaido Hospital fluoros-
copy system described in Sec. II D 3 to image continuously
for 2 min per fraction, over 30 fractions. The treatment site is
the lung, the technique is 100 kVp, 80 mA and 4 ms pulsed
exposure. The inherent x-ray filtration is 3.5 mm aluminum
equivalent.71 The exposure area for each imaging view is
266 cm2, for a total of 532 cm2. From Table II one finds the
dose-in-air per minute at the isocenter is 14.82 mGy. From
Tables IV and V for effective dose from planar radiographs
we average the AP and lateral factors to account for the
oblique imaging angle in Fig. 1, giving a total effective dose
of 1.75 mSv per fraction, or 52 mSv over the course of treat-
ment. With the addition of a treatment planning CT the pa-
tient receives a total of 60 mSv of imaging dose, correspond-
ing to a 0.3% additional risk of radiation-induced cancer.
IV.C. Comparison of imaging dose to concomitant
dose from the therapy beam
At some point an evaluation of imaging dose in IGRT
must involve comparisons to primary and secondary con-
comitant dose from the treatment beam. We have already
indicated that this is a nontrivial problem for two reasons: 1
therapy dose distributions are far more individualized than
imaging doses, and 2 the estimation of effective dose from
the therapy beam has rarely been attempted. Therefore the
task group did not undertake to study the problem of con-
comitant therapy dose or to compare imaging dose to pri-
mary and secondary therapy dose. However, we provide here
some examples of secondary therapy dose estimations to
provide the practitioner with some direction in making case-
by-case clinical evaluations.
Secondary treatment dose has two principal components:
1 An external component from collimator leakage, scatter
from materials outside of the patient, etc. and 2 an internal
component from interactions of the primary therapy beam
with the patient.
In a phantom/simulation study, Diallo et al.84 developed a
computational program to estimate total internal and external
scattered dose to anatomy outside the target volume for a
comprehensive range of treatment variables. By entering
patient-specific parameters such as treatment site, patient
height and weight, and treatment beam characteristics, etc.,
the user obtains a map of concomitant dose elsewhere in the
body. In two examples, a 60 Gy breast treatment delivered
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60 Gy head/neck treatment to a target near the base of the
skull delivered 240 mGy to the pectoral region of the chest.
As one would expect, the secondary dose falls off rapidly
with distance from the treatment site, making it difficult to
summarize or compare to distributions of imaging dose.
In a clinical case study of one example prostate IMRT
treatment, Cigna et al.85 measured the total scattered dose
from both internal and external a 6 MV Varian Clinac
6/100 sources using ten pen dosimeters arranged at various
points on the surface of the patient’s body. Again, the geo-
metrical distribution of scattered dose fell off steeply with
distance from the target e.g., by a factor of approximately
25 in the first 10 cm away from the isocenter. From their
measurements the authors calculated a total secondary effec-
tive dose of 854 mSv produced by a total primary target dose
of 70.2 Gy. The presentation of the results in terms of effec-
tive dose properly accounts for both the geometric dose dis-
tribution and differing radiosensitivity within the anatomy. It
is important to note that more than 34 of the effective dose for
this particular treatment scenario was due to exposure of the
testes, which are close to the target and have a high radiosen-
sitivity.
We also take note of a Monte Carlo simulation of inter-
nally scattered secondary radiation in a phantom, by Ing et
al.,86 who report their results in total integrated dose gram -
mGy over the entire phantom volume. This study does not
allow direct comparison to the other two estimates cited
here, as the integration in cGy over volume washes out the
falloff with distance from the target without making the con-
version to integral effective dose.
Perhaps the most significant point to be made by these
examples is that the secondary therapy dose is dominated by
internal scatter, which depends on many clinical parameters
beam energy spectrum, geometry of fields, position of treat-
ment site, patient shape and size, IMRT versus 3D versus
conventional that vary significantly from one patient to the
next. While it is feasible to collect imaging doses from stan-
dardized imaging techniques into a report such as this, it may
never be feasible to summarize concomitant therapy dose in
a comparable way.
V. DOSE REDUCTION AND OPTIMIZATION
The general rule adopted for dose management in diag-
nostic imaging is represented by the acronym ALARA—as
low as reasonably achievable. For imaging associated with
radiotherapy we will address methods to reduce the effective
dose without reducing the image information, e.g., by nar-
rowing fields of view, using more efficient imaging modes
and techniques, etc.
In diagnostic imaging there is a direct relationship be-
tween exposure level and image quality. The demand for
high contrast, low-noise images pushes the exposure levels
up. In IGRT, the beam alignment information derived from
images used for the targeting of tumors is less dependent on
image quality and more dependent on imaging frequency. In
each general treatment scenario, an increase in the number of
4059 Murphy et al.: Imaging dose during image-guided radiotherapy 4059images will yield smaller errors in dose alignment, but with
diminishing significance. At some point, further increases in
the number of images will add more imaging radiation dose
to healthy tissue than is eliminated by improved therapy dose
alignment. One would like to identify this point of optimal
balance between imaging dose and alignment error.
V.A. Field collimation
The U.S. Federal regulations for limiting exposure in di-
agnostic x-ray imaging require only that the field of view
illuminated by the source not exceed the area of the sensor,
since imaging exposure outside the imaging active area is
obviously of no use. This is a necessary but not sufficient
guideline for the reduction of unnecessary exposure. In fact,
in image-guided setup and tracking all exposed volume out-
side the anatomy actually used to align patient and beam
receives unnecessary dose that contributes nothing to the im-
age guidance process. For a treatment in which a small clus-
ter of fiducials within the tumor serves for beam alignment,
the relevant targeting cross section can be as small as 5 cm
in diameter 20 cm2, while a 9 in. x-ray image intensifier or
a 2020 cm amorphous silicon panel has approximately
400 cm2 of active area.
Effective dose is inherently an integral measure of dose,
involving field area for planar radiography and scan length
for tomography. Effective dose can be reduced by employing
adjustable collimators that can limit the radiation field to the
immediate vicinity of the target anatomy. This has been
implemented in, e.g., the CyberKnife and the BrainLab
Novalis x-ray alignment systems. Likewise, for in-room CT
verification, it is recommended that one scan only as much
anatomy as necessary for the desired imaging task, such as
positioning a particular region of anatomy. This can be
achieved easily by limiting the axial length of the scan in a
slice-based scanner such as CT-on-rails or TomoTherapy, or
by reducing the cone angle in the axial direction in cone-
beam CT. It can also be achieved in both axial and cone-
beam CT by restricting the field of view in the slice direction
by collimating down the fan angle to the volume of
interest,87,88 but the resulting truncation of the projection data
produces artifacts from filtered backprojection, necessitating
a more sophisticated reconstruction process. Therefore re-
duction of the effective dose for CT by reducing the exposed
volume is a more difficult process than for planar radiogra-
phy. Nevertheless, a significant reduction factor of 10 of
effective dose in megavoltage CT has been achieved by re-
ducing the fan angle without loss of image quality.87
V.B. Pulsed fluoroscopy
Standard fluoroscopy acquires images at the standard
video rate of approximately 15 or 30 frames per second. The
exposure level is set to give an acceptable image of the
anatomy in each frame. Fluoroscopy in IGRT is frequently
used to monitor the motion of target sites that move due to
respiration and heartbeat, often using implanted fiducials to
mark the target. Fluoroscopic exposure can be reduced by
three means: 1 Reduction of the exposure period while
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2 reduction of the frame rate while maintaining the conven-
tional exposure period of 32 ms; or 3 reduction of both the
frame rate and the exposure period. At Hokkaido University
the prototype fluoroscopic tracking system takes 30 frames
per second of either 2 or 4 ms duration.11 Normal respiration
occurs at a frequency of 0.3–1 cycles per second while nor-
mal heartbeat is below 2 cycles per second. Typically there is
not much tumor motion above a few cycles per second.2
Therefore, if one wants to reconstruct motion trajectories due
to heartbeat and respiration it should be sufficient to take
measurements at 3–4 cycles per second, each of 32 ms du-
ration, by pulsing the source. This would reduce the fluoro-
scopic dose by an order of magnitude from the conventional
exposure and make quasi-continuous fluoroscopy a very vi-
able technique for continuous tumor tracking even during
single fraction radiosurgery. This type of reduced frame rate
capability has been introduced in the second-generation
Hokkaido-type system.71
However, fluoroscopic sampling of the tumor position
must allow for motion of the internal organ that is sometimes
unpredictable,56,89 and the latency between the image acqui-
sition and delivery of therapeutic beam must be short90 to
prevent large errors in compensating the system lag time.
This puts limits on the amount of acceptable exposure reduc-
tion.
V.C. Nonradiographic imaging and hybrid imaging/
tracking
X-ray imaging is not the only way to locate tumors before
and during treatment. Nonradiographic localization using im-
planted electromagnetic transponders has recently been
demonstrated91 and offers an alternative or supplement to
x-ray imaging modalities to locate treatment sites that have
been marked by implanted fiducials. Although this is an in-
vasive technique that is applicable only to sites into which
markers can be placed, it provides continuous position infor-
mation that allows one to significantly reduce or even elimi-
nate the imaging duty cycle without a loss of position accu-
racy.
There is also an effort underway to demonstrate magnetic
resonance imaging in the treatment room by integrating an
MR system with a linac radiation delivery device.92 If suc-
cessful, this development will allow not only pretreatment
setup using MR, but intrafraction monitoring as well, leaving
x-ray techniques for treatment planning CT and real-time
motion adaptation fluoroscopy.
VI. SUMMARY AND RECOMMENDATIONS
Image-guided radiotherapy IGRT is the new paradigm
for external-beam treatment delivery. For the foreseeable fu-
ture the imaging will be performed primarily with radio-
graphic modalities, which add more radiation dose to the
already high dose burden to the patient, in ways that are
fundamentally different from the therapy itself. Good medi-
cal practice demands that the negative effects of this con-
comitant dose be reduced as much as possible.
4060 Murphy et al.: Imaging dose during image-guided radiotherapy 4060Reduction begins with assessment and so this task group
has been concerned primarily with surveying the variety of
radiographic imaging techniques currently or prospectively
used during radiotherapy. This survey has collected into one
place a description of the basic imaging modalities and their
typical configurations for IGRT, a summary of approximate
doses delivered by each modality as a function of patient
characteristics and treatment site, examples of the imaging
scenarios currently employed in the treatment process, and
an outline of the procedure for computing a composite im-
aging dose from the various procedures used in a given treat-
ment.
We have attempted to provide enough data for represen-
tative IGRT imaging systems to allow the reader to estimate
dose for other systems and configurations present and fu-
ture using general scaling principles for x-ray technique
linear in mAs, geometry 1/ r2, and other physical param-
eters. However, some readers may wish to undertake mea-
surements for specific applications. We refer them to the re-
port of AAPM Task Group 834 for measuring radiographic
entrance skin exposure, mammography exposure, and CTDI,
Islam et al.42 for CBCT measurements, and Tremain et al.22
for C-arm fluoroscopy measurements.
The task group recommends that practitioners of IGRT
use this survey information to do the following six things:
1 In all IGRT treatments, compile a complete picture of all
of the imaging procedures to be used before, during, and
after treatment;
2 Identify those image-guidance steps that can potentially
be accomplished without the use of ionizing radiation;
3 Configure the image acquisition systems to eliminate
dose outside the required FOVs;
4 Plan the imaging technique to be consistent with the
image quality and information needed for the treatment
decision being made;
5 After arriving at an IGRT imaging scenario that elimi-
nates un-needed dose and optimizes the required expo-
sure, use the resources of this report to estimate the total
effective imaging dose, from all sources, that the patient
will receive;
6 Evaluate the total dose patient-by-patient using guide-
lines for estimating stochastic and deterministic risk,
with the understanding that the diagnostic imaging com-
munity relies on judgment rather than prescription in
assessing individual exposure risk.
In conservatively designed IGRT procedures, the added
risk associated with imaging dose will usually be negligible.
In these cases the final recommendation is to think
economically—unused dose identified in one procedure can
be spent instead in other procedures where it can add useful
information.
For researchers and vendors advancing the technology of
IGRT, the task group recommends that each role of imaging
in the therapeutic process be analyzed for its dependence on
ionizing radiation. X-ray imaging will always be a primary
tool in IGRT but dose reduction provides an important incen-
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ods wherever possible. It is further recommended that strat-
egies for reducing the imaging dose and volume of exposed
anatomy be pursued wherever possible, even when they re-
quire developing new image acquisition and reconstruction
techniques. Vendors should be encouraged to provide pulsed
fluoroscopy, adjustable FOV collimation, continuously ad-
justable LINAC output for portal imaging, and limited FOV
CT reconstruction algorithms, etc. The rationale for this is
simple—we want to spend only as much imaging dose as is
required to effect a net gain in the quality of treatment. If the
information requirements of today’s IGRT had to be met us-
ing the radiographic technologies of 25 years ago, the patient
exposure levels would almost certainly be unacceptably
high.
Physicists and physicians frequently attempt comparisons
of imaging and therapy dose but we have already pointed out
that this is problematic when it is done simply by comparing
air kerma or CTDI to the treatment dose measured in units of
Gy. This is not even appropriate for comparisons among dif-
ferent imaging modalities.33 Effective dose in mSv is the
correct quantity to use for these comparisons, but because
treatment scenarios are far more varied than imaging sce-
narios there have been very few attempts at estimating effec-
tive dose from the therapy beam. The task group recom-
mends that the image-guided radiotherapy community
investigate calculations of effective dose from the primary
and scattered therapy beam so that imaging and therapy dose
can be properly compared.
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